Actively Recruiting
The Safety and Effectiveness of NEPA in Preventing Postoperative Nausea and Vomiting After General Anesthesia Gastrointestinal Cancer Surgery: A Single-Center Retrospective Study
Led by Tianjin Medical University Cancer Institute and Hospital · Updated on 2024-05-16
50
Participants Needed
1
Research Sites
137 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The rapid progress of multiple antiemetic regimens ensures that patients can receive full dose chemotherapy, however, there are still a large number of unmet clinical needs in patient evaluation and treatment. Due to the fact that patients with liver, gallbladder, and pancreatic diseases undergoing surgery are still in the stage of nausea and vomiting, the actual incidence of delayed nausea and vomiting may be underestimated. The long-term effective control of nausea and vomiting by Nitopitan Palonosetron capsules may improve the quality of life of patients during and after treatment, and ultimately improve clinical outcomes
CONDITIONS
Official Title
The Safety and Effectiveness of NEPA in Preventing Postoperative Nausea and Vomiting After General Anesthesia Gastrointestinal Cancer Surgery: A Single-Center Retrospective Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female, aged 18-65 years old
- Diagnosed with liver, gallbladder, or pancreatic diseases by histology or cytology
- Undergoing elective surgery such as pancreaticoduodenectomy, liver resection, or bile duct stone removal
- Treated with Netopitam Palonosetron capsules
- Not currently breastfeeding
- Negative pregnancy test if female with potential pregnancy
- Willing to follow the study protocol and provide written informed consent
You will not qualify if you...
- Serious untreated liver, kidney, or cardiopulmonary dysfunction
- History of serious mental illness
- Used antiemetics or antidepressants within 48 hours before surgery
- Received systemic glucocorticoid treatment within 4 weeks before surgery
- Used NK1 receptor antagonists or investigational drugs within 4 weeks before the study
- Used CYP3A4 inducers within 4 weeks before surgery or CYP3A4 substrates/moderate to potent inhibitors within 1 week
- Pregnant or breastfeeding women or those unwilling/unable to use effective contraception
- Drug or alcohol abuse
- Hypocalcemia or other conditions causing vomiting
- Allergy to Netopitam Palonosetron capsules or its ingredients
- Participated in another clinical study with investigational drugs or devices within 30 days before baseline
- Other conditions deemed by researchers to affect study progress or results
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China, 300060
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here